Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout

2024-03-11 Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND […]

Medicilon 20th Anniversary – Keep pace with the times in innovation, thanks for having you

2024-02-28 In 2024, Medicilon will celebrate its 20th anniversary.  At the time of departure, Medicilon shouldered the dream of China’s new drug research and development, took root in Zhangjiang, Shanghai, and embarked on a long journey to pursue the dream.  During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D […]

Search Medicilon

Preclinical CRO

ACS Fall 2026

Preclinical CRO

【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026

Preclinical CRO

World’s First Phase III Positive B7-H3 ADC: Medicilon Congratulates MediLink Therapeutics on NDA Acceptance of Icontamrotamab

Contact Medicilon

Name(Required)
Address(Required)